NovoCure Ltd (NVCR) stock: key figures, P/E, revenue and dividend
Health Care · ISIN USG6674U1081
NovoCure Ltd financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 655.35 m USD |
| Gross profit | 488.47 m USD |
| Operating income | -153.80 m USD |
| EBIT | -126.91 m USD |
| Net income | -136.23 m USD |
| Diluted EPS – continuing operations | -1.22 USD |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About NovoCure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
More stocks
- Guangdong Advertising Co Ltd (002400.SZ)
- Cymbria Corporation (CYB.TO)
- Sanquan Food Co Ltd (002216.SZ)
- DTR Automotive (007340.KS)
- Beijing Caishikou Department Store Co Ltd (605599.SS)
- Lu-Ve SpA (LUVE.MI)
- Mota Engil SGPS SA (EGL.LS)
- Nippn Corp (2001.T)
- Shenzhen Edadoc Technology Co. Ltd. A (301366.SZ)
- Jiangsu Hualan New Pharmaceutical Material Co. Ltd. (301093.SZ)
- Yusys Technologies Co Ltd Class A (300674.SZ)
- FLEX LNG Ltd (FLNG)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.